Instruction for use: Dobutamin Solvay

Active substance Dobutamine

ATX Code C01CA07 dobutamine

Pharmacotherapeutic group:

Cardiac glycosides and cardiac facilities neglikozidnye

Beta-adrenergic agonist

The nosological classification (ICD-10)

I21 Acute myocardial infarction

Myocardial infarction in the acute phase, Acute Myocardial Infarction, Myocardial infarction with pathologic Q wave and without, Myocardial infarction complicated by cardiogenic shock, Infarction left ventricular, Transmural myocardial infarction, Myocardial infarction netransmuralny (subendocardial), Netransmuralny myocardial infarction, Subendocardial myocardial infarction, The acute phase of myocardial infarction, Acute myocardial infarction, Sub-acute phase of myocardial infarction, Subacute phase of myocardial infarction, Thrombosis of the coronary arteries (the arteries), Threatened myocardial infarction, Myocardial infarction without Q wave

I50.0 Congestive heart failure

anasarca heart, Decompensated congestive heart failure, Congestive heart failure, Congestive heart failure with high afterload, Congestive chronic heart failure, Cardiomyopathy with severe chronic heart failure, Compensated chronic heart failure, Swelling with circulatory failure, Edema of cardiac origin, Swelling of the heart, Edematous syndrome in diseases of the heart, Edematous syndrome in congestive heart failure, Edematous syndrome in heart failure, Edematous syndrome in heart failure or liver cirrhosis, right ventricular failure, Congestive Heart Failure, Heart failure stagnant, Heart failure with low cardiac output, Heart failure is a chronic, Cardiac edema, Chronic decompensated heart failure, Chronic Congestive Heart Failure, Chronic heart failure, Change of liver function in heart failure

I50.1 Left ventricular failure

Asthma heart, Asymptomatic left ventricular dysfunction, Asymptomatic left ventricular heart failure, Diastolic left ventricular dysfunction, Left ventricular dysfunction, Changes in left ventricular myocardial infarction, Left ventricular heart failure, Left ventricular dysfunction, Acute left ventricular failure, Acute cardiac left ventricular failure, cardiac asthma, Left ventricular heart failure, Changes in left ventricular failure with pulmonary, Precordial abnormal pulsation, Insufficiency of the left ventricle

R07.2 Pain in the heart

neuroses of the heart, Myocardial ischemic pain, Pain syndrome in myocardial infarction, cardialgia, cardioneurosis, Cardiac syndrome, Pain in cardiac patients, Cardialgia on background dyshormonal myocardial dystrophy, Functional cardialgia, Psevdostenokardiya, pericardial pain

R57.0 Cardiogenic shock

cardiogenic shock

Structure and Composition

The solution for infusion 250 mg / 50 ml 1 amp.

dobutamine hydrochloride 280 mg

(Corresponding to 250 mg of dobutamine)

excipients: L-cysteine hydrochloride hydrate; citric acid monohydrate; sodium chloride, sodium hydroxide, water for injections

in vials of 51 ml; 1 ampoule per carton.

pharmachologic effect

pharmachological effect

hypertensive, cardiotonic.

It stimulates the beta1-adrenergic receptors of myocardium. It has a moderate positive chronotropic effect. It increases stroke volume and cardiac output, reduces peripheral vascular resistance and pulmonary vascular resistance.

Indications of dobutamin Solvey®

Heart failure (acute exacerbation of chronic), inotropic therapy for heart failure associated with low cardiac output on a background of myocardial infarction; while in the open heart surgery, cardiomyopathies, septic shock, cardiogenic shock.

Contraindications

Hypersensitivity, idiopathic hypertrophic subaortic stenosis, cardiac tamponade, pericarditis,

Pregnancy and breast-feeding

Perhaps if the expected effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.

Side effects

Tachycardia (including ventricular), atrial fibrillation, palpitations, pain in the heart and chest, shortness of breath, increased blood pressure, or hypotension, headache, nausea, hypokalemia, petechial bleeding, phlebitis, allergic reactions (skin rash, fever, bronchospasm , eosinophilia, etc..), skin necrosis (in the introduction) in contact with the skin.

Interaction

Beta-blockers reduce the positive inotropic effect. MAO inhibitors enhance the unpredictable Adrenomimeticalkie activity (risk of hypertensive crisis, cardiac arrhythmias). Venous vasodilators (nitrates, sodium nitroprusside) in the combined use with dobutamine increase increase in cardiac output, marked reduction in systemic vascular resistance and ventricular filling pressure. Simultaneous treatment with ACE inhibitors (including captopril) and high doses of dobutamine increases cardiac output, increased consumption of cardiac muscle oxygen (possible appearance of pain in the heart and heart rhythm disturbances).

Combined dopamine dobutamine is - depending on the dose of dopamine pronounced increase in blood pressure.

Dosing and Administration

B / in. The dose is adjusted individually. The recommended dose for adults - 2.5-10 mg / kg / min, and in some cases - up to 40 mcg / kg / min; for children - 1-15 mcg / kg / min (there is evidence that the minimal effective dose for children is higher than in adults); at high doses, caution is necessary, because at the same time there is evidence that the maximum tolerated dose for children is lower than for adults. At doses greater than or equal to 7.5 ug / kg / min, the greatest number of observed side effects (especially tachycardia).

Before the abolition of the drug to gradually reduce the dose!

Instructions for the preparation of infusion solution: Dobutamine Solvay as a solution for the on / in the ampoules in a 50 ml is used undiluted in the infusion drip. Alternatively, the preparation can be pre-diluted 5% glucose solution, saline, Ringer's lactate.

Use only for the on / in the introduction.

Due to the short drug withdrawal period should be entered in / in continuously.

During the administration of dobutamine Solvay should monitor heart rate, blood pressure, urine output, the volume of infusion and injection speed. If possible, during infusion should be monitored value of cardiac output, central venous pressure and pulmonary capillary pressure.

Duration / in the clinical symptoms depend on and is determined by the doctor.

With continuous use of the drug over 72 hours can develop tolerance, which makes it necessary to increase the dosage of the drug.

Precautionary measures

During treatment, mandatory monitoring of heart rate, cardiac output, blood pressure, venous pressure and pulmonary capillary pressure, urine output. Diabetic patients in the early treatment of dobutamine, when changing infusion rate, and at the termination of infusion is necessary to control blood glucose levels.

Storage conditions

In a dry, dark place at room temperature not exceeding 25 ° C. Do not freeze.

Keep out of the reach of children.

The shelf life

3 years.

Do not use beyond the expiration date printed on the package.